The PREVAILS study, now fully enrolled, marks a critical step toward simultaneous regulatory submissions in China and Europe for the next-generation TAVR system HANGZHOU, China, July 23, 2026 /PRNewswire/ — Venus Medtech (Hangzhou) Inc. (02500.HK) today announced that patient enrollment…
Other News
Ribo Discloses Positive Data from Vortosiran Phase 2a Trial – World’s First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease
SHANGHAI and MOLNDAL, Sweden, July 22, 2026 /PRNewswire/ — Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as “Ribo”) today announce at China Pharmaceutical Innovation Conference (CPIC) in Shanghai, the positive…
Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases
Collaboration combines Evogene’s AI-driven computational chemistry platform with ELEO’s proprietary biological capabilities to accelerate the discovery of novel oral therapies targeting a multi-billion-dollar cardiovascular market opportunity REHOVOT, Israel and DAEJEON, South Korea, July…
FDA Grants Orphan Drug Designation to Affinia Therapeutics’ AFTX-201 for the Treatment of BAG3-Associated Dilated Cardiomyopathy (DCM)
WALTHAM, Mass.–(BUSINESS WIRE)–Affinia Therapeutics (“Affinia”), an innovative clinical-stage gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for devastating cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for AFTX-201 for the treatment of BAG3-associated dilated cardiomyopathy (DCM). A potential best-in-class investigational genetic m
American Heart Association AI Assessment Lab Report Finds Ultromics’ EchoGo® Heart Failure May Identify HFpEF Earlier Than Standard Care
Powered by retrospective real-world data from Dandelion Health, the American Heart Association’s AI Impact Report provides a third-party evaluation of Ultromics’ EchoGo® Heart Failure The independent assessment shows EchoGo® Heart Failure could have identified HFpEF 263 days earlier than…
Rapid Medical Announces FDA Clearance of DRIVEWIRE™ 35 and First Stroke Cases
SEATTLE & YOKNEAM, Israel–(BUSINESS WIRE)– #DRIVEWIRE–Rapid Medical FDA-cleared DRIVEWIRE 35, first steerable 0.035-inch guidewire for stroke, neurovascular and peripheral access, after 5,000 DW24 cases.
FUJIFILM Sonosite Expands Portfolio with the Launch of Sonosite iLOOK, a Dedicated Ultrasound Solution for Vascular Access
BOTHELL, Wash.–(BUSINESS WIRE)–FUJIFILM Sonosite, Inc., a global leader in point-of-care ultrasound (POCUS) solutions, today announced the launch of Sonosite iLOOK, a compact ultrasound solution designed specifically for vascular access. Sonosite iLOOK combines a purpose-built user interface, wireless transducer technology, and flexible mounting options in a streamlined solution intended to support vascular access procedures at the bedside Developed specifically for vascular access workflows,
Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026
ST. LOUIS, July 21, 2026 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 second quarter on Tuesday, August 11, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments.
Karoo Health Announces Oversubscribed $16.2 Million Series A Co-Led by 7wire Ventures and Allumia Ventures
Proceeds will be used to advance the company’s AI-native cardiovascular platform and expand partnerships with health plans and cardiology practices nationwide ALBUQUERQUE, N.M., July 21, 2026 /PRNewswire/ — Karoo Health, a cardiovascular technology company building an operating system…
Vesalio Announces Late-Breaking Clinical Trial Presentation of the enVast NATURE Study at the ESC Congress 2026
NATURE trial, a prospective randomized controlled trial comparing the safety and effectiveness of thrombectomy using enVast before conventional PCI versus standard of care alone, was selected for the prestigious Late-Breaking Clinical Trials session at the European Society of Cardiology…


